157
Participants
Start Date
November 14, 2018
Primary Completion Date
March 13, 2020
Study Completion Date
May 26, 2020
Gadoterate (Dotarem/Clariscan)
Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.
Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
Inselspital Universitätsspital Bern, Bern
Kantonsspital Aarau, Aarau
Mount Sinai Hospital, New York
Penn State Milton S. Hershey Medical Center, Hershey
Universität Rostock - Medizinische Fakultät, Rostock
Universitätsklinikum Schleswig-Holstein / AÖR, Lübeck
Universitätsklinikum Schleswig-Holstein (UKSH), Kiel
ULSS2 Marca Trevigiana, Treviso
Ulsan University Hospital, Ulsan
A.O.U. Pisana, Pisa
Northwestern University, Chicago
CHU STRASBOURG - Hôpital de Hautepierre, Strasbourg
Centre Hospitalier Lyon Sud, Pierre-Bénite
ASL Provincia di Barletta-Andria-Trani, Andria
University of Texas Southwestern Medical Center, Dallas
Universitätsklinikum Erlangen, Erlangen
Universitätsklinikum Leipzig AöR, Leipzig
Friedrich-Schiller-Uni. Jena, Jena
Seoul National University Hospital, Seoul
Royal Preston Hospital, Preston
Lead Sponsor
Bayer
INDUSTRY